Researchers explain why tackling brain inflammation and mixed proteins together is key to treating Parkinson's

Scientists Jhodi Webster and Ashley Harms have published a comprehensive review in npj Parkinson's Disease explaining why focusing on just one target might not be enough to slow down or stop Parkinson's. For decades, scientific research has largely concentrated on a single culprit called alpha synuclein. This is a normal protein that, in Parkinson's, loses its usual shape, turns sticky, and clumps together inside brain cells. The latest findings show that what happens in the brain is rarely that straightforward, and real progress will likely require tackling several biological problems at the same time. Looking closely at brain tissue reveals that more than half of people with Parkinson's also have other faulty proteins building up alongside alpha synuclein. The two most common are amyloid beta and tau, which are the main proteins usually linked with Alzheimer's. When these different proteins appear together in the brain, they do not just sit quietly side by side. Instead, they encourage each other to spread and clump faster, creating a far harsher environment for delicate nerve cells. This combined build up is closely connected to earlier and more noticeable difficulties with memory, thinking speed, and everyday problem solving. A major driving force behind this problem is chronic inflammation in the brain. The brain has its own built in defence system made up of specialised immune cells called microglia. In a healthy brain, these cells act like tidy caretakers, patrolling the area, cleaning up cellular rubbish, and protecting healthy tissue from harm. When sticky alpha synuclein combines with tau and amyloid, these caretaker cells become overwhelmed and get stuck in a constant state of high alert. Instead of protecting the brain, this ongoing irritation causes them to release damaging chemical signals that actively harm nearby healthy nerve cells. This triggers a damaging loop that keeps feeding itself. When nerve cells are put under constant stress by inflammation, their internal waste disposal systems break down, making it much harder for them to clear out faulty proteins. As more clumps form, they irritate the immune cells even further, which produces more inflammation. Webster and Harms point out that trying to remove alpha synuclein on its own is like trying to put out part of a fire while leaving the rest of the flames and the underlying heat untouched. To break this loop, the authors argue for a major change in how treatments are developed. Rather than searching for one single wonder drug to do everything, the most promising approach is combination therapy, which means using several targeted treatments together. A future treatment plan could combine a medicine designed to clear away alpha synuclein clumps, a calming drug to turn down the overactive immune response, and additional therapies to support cellular power stations or clear away tau where needed. Recent improvements in testing methods are bringing this tailored approach closer to everyday reality. New types of brain scans can now spot where immune cells are overactive, while sensitive laboratory tests can detect microscopic traces of clumped proteins in spinal fluid. By measuring these biological clues, doctors will eventually be able to identify the exact mix of inflammation and protein build up happening inside each person, allowing them to match the individual with the right combination of therapies to protect their brain cells.